𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical perspectives of bispecific antibodies in cancer

✍ Scribed by G. C. de Gast; J. G. J. van de Winkel; Bert E. J. E. G. Bast

Publisher
Springer-Verlag
Year
1997
Tongue
English
Weight
126 KB
Volume
45
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bispecific antibodies in cancer therapy
Bispecific antibodies in cancer therapy
✍ David M Segal; George J Weiner; Louis M Weiner πŸ“‚ Article πŸ“… 1999 πŸ› Elsevier Science 🌐 English βš– 58 KB

Abbreviations bsAb bispecific antibody

Role of target antigen in bispecific-ant
Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A pre-clinical study
✍ Achim Pfosser; Martina Brandl; Helmut Salih; Ludger Grosse-Hovest; Gundram Jung πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 85 KB πŸ‘ 1 views

Bispecific antibodies (bsAbs) directed to tumor-associated antigens and to receptors mediating T-cell activation, such as the TCR/CD3 complex and the co-stimulatory CD28 molecule, are capable of activating T cells at the surface of tumor cells, resulting in tumor-cell killing. Here we report the pre

Bispecific antibody targeting of doxorub
Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen–expressing colon cancer cell lines in vitro and in vivo
✍ C.H.J. Ford; P.A. Osborne; B.G. Rego; A. Mathew πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 120 KB

A bispecific monoclonal antibody (BsMAb) recognising carcinoembryonic antigen (CEA) and doxorubicin (Dox) was used in colorimetric microcytotoxicity assays with 3 human colon cancer cell lines (COLO320DM, SKCO1 and LS174T) showing no, high or medium CEA expression, respectively. The IC50 values for